A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
Open Access
- 10 August 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 213 (3), 411-422
- https://doi.org/10.1093/infdis/jiv406
Abstract
Background. Respiratory syncytial virus (RSV) is a leading cause of infant morbidity and mortality. A recombinant RSV fusion protein nanoparticle vaccine (RSV F vaccine) candidate for maternal immunization was tested for safety and immunogenicity in women of childbearing age. Methods. Three hundred thirty women (18–35 years) were randomized to receive 1 or 2 doses of RSV F vaccine (60 or 90 µg) with or without aluminum phosphate adjuvant, or placebo at days 0 and 28. Safety was evaluated over 180 days; immunogenicity and RSV infection rates were evaluated over 112 days. Results. All vaccine formulations were well tolerated, without vaccine-related serious adverse events. Anti-F immunoglobulin G antibodies rose 6.5–15.6-fold, with significantly higher levels in 2-dose, adjuvanted regimens at day 56. Palivizumab-competitive antibody levels were undetectable at day 0 but increased up to 325 µg/mL at day 56. A 2.7- and 3.5-fold rise in RSV/A and RSV/B microneutralization antibodies were noted at day 56. Between days 56 and 112, 21% (12/56) of placebo recipients and 11% of vaccinees (26/244) showed evidence of a recent RSV infection (P = .04). Conclusions. The vaccine appeared safe, immunogenic, and reduced RSV infections. Further development as a vaccine for use in maternal immunization is warranted. Clinical Trials Registration. NCT01704365.Keywords
This publication has 31 references indexed in Scilit:
- Gene Sequence Variability of the Three Surface Proteins of Human Respiratory Syncytial Virus (HRSV) in TexasPLOS ONE, 2014
- Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineVaccine, 2012
- Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997–2006The Pediatric Infectious Disease Journal, 2012
- A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart DiseasePediatric Research, 2011
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersProceedings of the National Academy of Sciences of the United States of America, 2011
- Prevention of serious respiratory syncytial virus-related illness. II: ImmunoprophylaxisAdvances in Therapy, 2011
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority TrialPublished by American Academy of Pediatrics (AAP) ,2010
- Rates of hospitalization for respiratory syncytial virus infection among children in MedicaidThe Journal of Pediatrics, 2000
- Risk of Primary Infection and Reinfection With Respiratory Syncytial VirusArchives of Pediatrics & Adolescent Medicine, 1986